Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , may represent a promising step forward for obesity loss . Initial patient tests have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide